Insulin biosimilars can better simulate the human physiological state of insulin secretion patterns, reduce the risk of hypoglycemia, achieve a more flexible dosing time, improve patient compliance, and reduce diabetic complications (Hilgenfeld et al., 2014). This evidence concerns the gene INS and Hypoglycemia.